Relevant bibliographies by topics / Rheumatic

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Rheumatic'

Author: Grafiati
Published: 4 June 2021
Last updated: 11 March 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Rheumatic.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Rheumatic"

1

Kostine, Marie, Marie-Elise Truchetet, and Thierry Schaeverbeke. "Clinical characteristics of rheumatic syndromes associated with checkpoint inhibitors therapy." Rheumatology 58, Supplement_7 (December 1, 2019): vii68—vii74. http://dx.doi.org/10.1093/rheumatology/kez295.

Full text
Abstract:
AbstractCompared with conventional cancer therapies, the spectrum of toxicities observed with checkpoint inhibitors is unique and can affect any organ system. Arthralgia and myalgia were by far the most commonly reported rheumatic immune-related adverse events in clinical trials, and there is now a growing number of case series and reports describing clinical features of de novo rheumatic immune-related adverse events, which will be the focus of this review. Some patients develop genuine classic rheumatic and musculoskeletal diseases, but a number of rheumatic immune-related adverse events mimic rheumatic and musculoskeletal diseases with atypical features, mainly polymyalgia rheumatica, rheumatoid arthritis and myositis, as well as several systemic conditions, including sicca syndrome, vasculitis, sarcoidosis, systemic sclerosis and lupus.
APA, Harvard, Vancouver, ISO, and other styles
2

Kemeny-Beke, Adam, and Peter Szodoray. "Ocular manifestations of rheumatic diseases." International Ophthalmology 40, no. 2 (October 3, 2019): 503–10. http://dx.doi.org/10.1007/s10792-019-01183-9.

Full text
Abstract:
Abstract Purpose Our aim was to summarize key aspects of the pathomechanism and the ocular involvements of rheumatic and systemic autoimmune diseases. Methods Apart from a paper in French (Morax V, Ann Oculist 109:368–370, 1893), all papers referred to in this article were published in English. All the materials were peer-reviewed full-text papers, letters, reviews, or book chapters obtained through a literature search of the PubMed database using the keywords ocular manifestations; pathogenesis; systemic inflammatory rheumatic diseases; rheumatoid arthritis; osteoarthritis; fibromyalgia; systemic lupus erythematosus; seronegative spondyloarthritis; ankylosing spondylitis; reactive arthritis; enteropathic arthritis; psoriatic arthritis; systemic sclerosis; polymyalgia rheumatica and covering all years available. Some statements articulated in this paper reflect the clinical experience of the authors in their tertiary-referral center. Results Ophthalmic disorders are categorized by anatomical subgroups in all rheumatic diseases. The most common ocular manifestations are diverse types of inflammations of different tissues and dry eye disease (DED). Conclusion The eye could be a responsive marker for the onset or aggravation of an immune reactivation in many rheumatic diseases, furthermore, ocular findings can antedate the diagnosis of the underlying rheumatic disease. By recognizing ocular manifestations of systemic rheumatic diseases it might be possible to avoid or at least delay many long term sequelae.
APA, Harvard, Vancouver, ISO, and other styles
3

Kostine, Marie, Léa Rouxel, Thomas Barnetche, Rémi Veillon, Florent Martin, Caroline Dutriaux, Léa Dousset, et al. "Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer—clinical aspects and relationship with tumour response: a single-centre prospective cohort study." Annals of the Rheumatic Diseases 77, no. 3 (November 16, 2017): 393–98. http://dx.doi.org/10.1136/annrheumdis-2017-212257.

Full text
Abstract:
ObjectivesTo evaluate the prevalence and type of rheumatic immune-related adverse events (irAEs) in patients receiving immune checkpoint inhibitors (ICIs), as well as the correlation with tumour response.MethodsThis was a single-centre prospective observational study including all cancer patients receiving ICIs. The occurrence of irAEs and tumour response was assessed on a regular basis. Patients who experienced musculoskeletal symptoms were referred to the department of rheumatology for clinical evaluation and management.ResultsFrom September 2015 to May 2017, 524 patients received ICIs and 35 were referred to the department of rheumatology (6.6%). All but one of the rheumatic irAEs occurred with anti-programmed cell death protein 1(PD-1)/PD-1 ligand 1(PD-L1) antibodies, with a median exposure time of 70 days. There were two distinct clinical presentations: (1) inflammatory arthritis (3.8%) mimicking either rheumatoid arthritis (n=7), polymyalgia rheumatica (n=11) or psoriatic arthritis (n=2) and (2) non-inflammatory musculoskeletal conditions (2.8%; n=15). One patient with rheumatoid arthritis was anti-cyclic citrullinated peptide (anti-CCP) positive. Nineteen patients required glucocorticoids, and methotrexate was started in two patients. Non-inflammatory disorders were managed with non-steroidal anti-inflammatory drugs, analgesics and/or physiotherapy. ICI treatment was pursued in all but one patient. Patients with rheumatic irAEs had a higher tumour response rate compared with patients without irAEs (85.7% vs 35.3%; P<0.0001).ConclusionSince ICIs are used with increasing frequency, knowledge of rheumatic irAEs and their management is of major interest. All patients were responsive either to low-to-moderate doses of prednisone or symptomatic therapies and did not require ICI discontinuation. Furthermore, tumour response was significantly higher in patients who experienced rheumatic irAEs.
APA, Harvard, Vancouver, ISO, and other styles
4

Nacar, N. E., N. B. Karaca, L. Kiliç, S. Kiraz, and E. Ünal. "AB1498 THE BIOPSYCHOSOCIAL-BASED EXERCISE MODEL VIA TELEREHABILITATION IN PATIENTS WITH INFLAMMATORY AND NON-INFLAMMATORY RHEUMATIC DISEASES: A PROSPECTIVE COHORT STUDY DURING THE COVID-19 PANDEMIC." Annals of the Rheumatic Diseases 81, Suppl 1 (May 23, 2022): 1852.2–1853. http://dx.doi.org/10.1136/annrheumdis-2022-eular.5022.

Full text
Abstract:
BackgroundDuring the COVID-19 pandemic, the patients with rheumatic disease in the biopsychosocial perspective have been adversely affected by social isolation, uncertainty, and the thought that their chronic disease will worsen and increase in their symptoms. ACR/EULAR (American College of Rheumatology / European League Against Rheumatism) defines recommendations about continuing current pharmacotherapy and the significance of the biopsychosocial approach and exercise for patients with rheumatic diseases during a COVID-19 infection 1, 2.ObjectivesThis study aims to investigate the effectiveness of the biopsychosocial exercise performed by telerehabilitation on biopsychosocial status, general health status, and anxiety-depression levels in the patients with inflammatory and non-inflammatory rheumatic diseases.MethodsFourteen patients with inflammatory rheumatic diseases (rheumatoid arthritis: 4; ankylosing spondylitis: 4; sjogren’s syndrome: 3; polymyalgia rheumatica: 2; and vasculitis: 1) and eight patients with non-inflammatory rheumatic diseases (fibromyalgia: 6; and osteoarthritis: 2) performed a biopsychosocial-based exercise model (named as “Bilişsel Egzersiz Terapi Yaklaşimi”-(BETY) in original; “Cognitive Exercise Therapy Approach” in English) via telerehabilitation continued for three sessions per week for 12 months 3. Outcome measures were Health Assessment Questionnaire (HAQ), Hospital Anxiety and Depression Scale (HADS), and BETY-Biopsychosocial Questionnaire (BETY-BQ) 4. All outcomes were measured baseline and at the 12th month. The Wilcoxon’s test was used for statistical analysis.ResultsAll of the 22 patients were female. The mean age was 57.4 and 55.8 years in the inflammatory and non-inflammatory rheumatic diseases groups respectively, and they had a mean BMI of 25.9 and 25.3 kg/m2. There was no significant difference by time for HAQ score (p = 0.125), HADS anxiety and depression (p = 0.916 and p = 0.663, respectively), and BETY-BQ score (p = 0.753) between the baseline and at the 12th month follow-up in the patients with inflammatory rheumatic diseases. Similarly, in the patients with non-inflammatory rheumatic diseases, there was no significant difference by time for HAQ score (p = 0.546), HADS anxiety and depression (p = 0.343 and p = 0.527, respectively), and BETY-BQ score (p = 0.068) between the baseline and at the 12th month follow-up.ConclusionThis study showed that biopsychosocial-based exercise through real-time telerehabilitation was able to maintain their conditions before pandemic in biopsychosocial status, general health, and anxiety-depression levels on the patients with inflammatory and non-inflammatory rheumatic diseases during COVID-19 pandemic period in one-year follow-up.References[1]England BR, Barber CE, Bergman M, Ranganath VK, Suter LG, Michaud K. Brief Report: adaptation of American College of Rheumatology Rheumatoid Arthritis Disease Activity and functional status measures for telehealth visits. Arthritis Care Res (Hoboken). 2020.[2]Landewé RB, Machado PM, Kroon F, Bijlsma HW, Burmester GR, Carmona L, Combe B, Galli M, Gossec L, Iagnocco A. EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2. Ann Rheum Dis. 2020;79(7):851-8.[3]Kisacik P, Unal E, Akman U, Yapali G, Karabulut E, Akdogan A. Investigating the effects of a multidimensional exercise program on symptoms and antiinflammatory status in female patients with ankylosing spondylitis. Complementary therapies in clinical practice. 2016;22:38-43.[4]Edibe Ü, Gamze A, KARACA NB, KİRAZ S, AKDOĞAN A, KALYONCU U, ERTENLİ Aİ, BİLGEN ŞA, KARADAĞ Ö, ERDEN A. Romatizmali hastalar için bir yaşam kalitesi ölçeğinin geliştirilmesi: madde havuzunun oluşturulmasi. Journal of Exercise Therapy and Rehabilitation. 2017;4(2):67-75.Disclosure of InterestsNone declared
APA, Harvard, Vancouver, ISO, and other styles
5

Lujano Negrete, A. Y., C. M. Skinner Taylor, L. Pérez Barbosa, F. Hernández, R. A. Rodriguez Chavez, L. G. Espinosa Banuelos, R. Moyeda Martinez, A. Cárdenas, and D. Á. Galarza-Delgado. "AB0842 CESAREAN SECTION IN MEXICAN WOMEN WITH AUTOIMMUNE RHEUMATIC DISEASES." Annals of the Rheumatic Diseases 80, Suppl 1 (May 19, 2021): 1444.2–1445. http://dx.doi.org/10.1136/annrheumdis-2021-eular.3679.

Full text
Abstract:
Background:Rheumatic diseases occur among women of childbearing age, adverse events during pregnancy in rheumatic diseases have been frequently reported. Mexico has one of the largest prevalence of cesarean section in women which negatively impacts the product.Objectives:The objective of this study is to describe the frequency of cesarean section in women with autoimmune rheumatic diseases compared to a control group.Methods:We conducted a cross-sectional and retrospective study in patients from the pregnancy and rheumatic diseases clinic, and the Obstetrics department form the University Hospital “Dr. José E. González” in Northeast Mexico. Women with autoimmune rheumatic diseases that gave birth between August 2017 to December 2020 were included. All the data, including the way of birth was retrieved from the clinical files.Results:One hundred and twelve patients were included (56 in the rheumatic disease group and 56 women without rheumatic diseases), two of them suffered miscarriage (one from the rheumatic disease group and 1 from the control group) giving a total of 110 products. The mean age was 29.6 years for the rheumatic patients and 24.6 for the control group. The most frequent rheumatic disease was RA in 22 patients (39.2%), followed by SLE in 13 patients (23.21%).From the 56 pregnancies on the rheumatic disease group more than half ended by cesarean section (n=33, 58.92%) and there were 22 simple vaginal delivery. Table 1. On the control group there were 24 cesarean section procedures and 31 simple vaginal delivery. The indications for cesarean sections are presented in Figure 1. No statistically significant difference was found on cesarean section prevalence between both groups (p=0.389).The most common indication for cesarean section in all patients was previous cesarean procedure. (n=12, 36.36%). There were more pathological fetal cardiotocographic changes (PFCC) as an indication for cesarean section on the rheumatic diseases group (n=11, p 0.002) compared with the control group (n=1).Conclusion:A higher prevalence of cesarean sections was found in women with rheumatic diseases versus women without rheumatic diseases, although this difference was not statistically significant. Studies with a higher sample size are necessary to elucidate the complications and differences between both groups.References:[1]Jara LJ, Cruz-Dominguez MDP, Saavedra MA. Impact of infections in autoimmune rheumatic diseases and pregnancy. Curr Opin Rheumatol. 2019;31(5):546-52.[2]Saavedra MA, Sánchez A, Bustamante R, Miranda-Hernández D, Soliz-Antezana J, Cruz-Domínguez P, et al. [Maternal and fetal outcome in Mexican women with rheumatoid arthritis]. Rev Med Inst Mex Seguro Soc. 2015;53 Suppl 1:S24-9.[3]Smeele HTW, Dolhain R. Current perspectives on fertility, pregnancy and childbirth in patients with Rheumatoid Arthritis. Semin Arthritis Rheum. 2019;49(3s):S32-s5.[4]Sugawara E, Kato M, Fujieda Y, Oku K, Bohgaki T, Yasuda S, et al. Pregnancy outcomes in women with rheumatic diseases: a real-world observational study in Japan. Lupus. 2019;28(12):1407-16.[5]Vinet É, Bernatsky S. Outcomes in Children Born to Women with Rheumatic Diseases. Rheum Dis Clin North Am. 2017;43(2):263-73.Table 1.Demographic charecteristicsDISEASEN (%)AGE, YEARS MEANDURATION OF DISEASE, YEARS MEANCESAREAN SECTIONSIMPLE VAGINAL DELIVERYOTHERSRA22 (39.2%)29.956.7711101 MiscarriageAPS9 (16.98)28.222.7781DM3(5.35%)203.521IA3(5.35%)21.5321SS4 (7.14%)30.254.7531JIA2 (3.57%)361511SLE13 (23.21)31.835.3375TOTAL5629.641509433322RA: Rheumatoid Arthritis, APS: Anti-phospholipid syndrome, DM: Dermatomyositis, IA: Idiopathic arthritis, SS: Sjogren syndrome, JIA: Juvenile idiopathic arthritis, SLE: Systemic Lupus ErythematosusDisclosure of Interests:None declared
APA, Harvard, Vancouver, ISO, and other styles
6

Afridon, Afridon. "FAKTOR-FAKTOR YANG BERHUBUNGAN DENGAN KEJADIAN REMATIK PADA PENDERITA REMATIK DI KELURAHAN VI SUKU WILAYAH KERJA PUSKESMAS TANAH GARAM KOTA SOLOK." Ensiklopedia Education Review 2, no. 1 (February 25, 2021): 1–10. http://dx.doi.org/10.33559/eer.v2i1.653.

Full text
Abstract:
Rheumatic disease is a disease affecting the joints and surrounding structures, consisting of more than 100 types. Rheumatoid Arthritis (RA) is a progressive autoimmune disease with chronic inflammation that attacks the musculoskeletal system but can involve the organs and systems of the body as a whole, characterized by swelling, joint pain and destruction of synovial tissue accompanied by movement disorders followed by premature death. This type of research is analytical, with a cross sectional design, where in this study, the dependent and independent variables will be observed at the same time, this method is expected to be known "Factors Associated with Rheumatic Incidence in Rheumatism Patients in Village VI Ethnic Work Area. Puskesmas Tanah Garam Kota Solok ". Based on the results of research conducted on 40 respondents, it can be concluded that there is a relationship between genetics and the incidence of rheumatism, there is a relationship between age and the incidence of rheumatism, there is a relationship between sex and the incidence of rheumatism, there is a relationship between obesity and the incidence of rheumatism and a relationship between lifestyle and incidence rheumatism in Kelurahan VI Tribe, Tanah Garam Public Health Center, Solok City.
APA, Harvard, Vancouver, ISO, and other styles
7

Djunarko, Ipang, Nanang Fakhrudin, Arief Nurrochmad, and Subagus Wahyuono. "Identification Bioactive Compound of Ethanol-Water Fraction of Coleus atropurpureus for Anti-rheumatic Rheumatism in CFA-induced Rats." Journal of Pharmaceutical Sciences and Community 19, no. 2 (November 30, 2022): 93–102. http://dx.doi.org/10.24071/jpsc.004746.

Full text
Abstract:
Nonsteroidal anti-inflammatory drugs are used for pain and to slow the progression of rheumatoid arthritis. Accordingly, the discovery of rheumatoid arthritis active compounds from the ethanol-water fraction Coleus atropurpureus (EWC) was conducted to characterize the isolated compounds as well as the anti-rheumatic effects of the EWC induced Complete Freund's Adjuvant (CFA). We conducted in vivo study in rats which were randomly divided into 5 groups. Group 1 was only given CFA as a negative control. Group 2 as positive control was orally exposed to diclofenac potassium (9 mg/BW). Three groups were given different EWCs orally as follows: 11.25 mg/BW, 22.5 mg/BW, and 45 mg/BW, respectively. Rheumatism rates were then compared with positive controls using a visual arthritic scoring system. The compounds identified by isolation of the EWC of Coleus atropurpureus predicted forskolin. The ethanol-water fraction Coleus atropurpureus did not act as an anti-rheumatic arthritis agent in CFA-induced rats.
APA, Harvard, Vancouver, ISO, and other styles
8

Gediz, Fusun, and Senol Kobak. "Immune Checkpoint Inhibitors-related Rheumatic Diseases: What Rheumatologist Should Know?" Current Rheumatology Reviews 15, no. 3 (July 31, 2019): 201–8. http://dx.doi.org/10.2174/1573397115666190119094736.

Full text
Abstract:
: Immune checkpoint inhibitors are revolutionized drugs for cancer immunotherapy in the last years. The mechanism of action of CPIs including the limitation of the activation of Tcells, and thus enhancing the self-immune response against tumour cells. Checkpointinhibitors( CPIs) may dysregulate the immune system, resulting in some toxicities. These toxicities or side effects are called Immune-related Adverse Events (IRAEs) that can potentially affect any organ and tissue. Rheumatic diseases due to checkpoint inhibitors are also reported in the literature. The spectrum of rheumatic manifestations are quite wide; the most common are arthralgia/arthritis, myalgia/myositis, polimyalgia rheumatica, lupus, rheumatoid arthritis, Sjögren’s syndrome. At the same time, these drugs can also cause an exacerbation of known rheumatologic disease. Treatment approaches for developing rheumatic findings due to checkpoint inhibitors should be multidisciplinary. There should be a close relationship between oncologists who follow-up these patients and rheumatologists. The rheumatic manifestations should be defined and treated early. In general, the musculoskeletal side effects are transient and may regress after stopping CPIs. The most commonly used medications are corticosteroids. Immunosuppressive drugs (HQ, MTX, anti-TNF-alpha, anti-IL-6) should be preferred when treatment is unresponsive or as steroid-sparing agents. : The aim of this review was to evaluate the checkpoint inhibitors-related rheumatologic findings and therapeutic strategies in light of recent literature data.
APA, Harvard, Vancouver, ISO, and other styles
9

Jatwani, K., K. Chugh, I. Tan, and S. Jatwani. "FRI0520 HOSPITALIZATIONS FOR HEMATOLOGICAL MALIGNANCIES WITH RHEUMATIC DISEASES: A NATIONAL INPATIENT SAMPLE ANALYSIS OF TEN YEARS (2005-2014)." Annals of the Rheumatic Diseases 79, Suppl 1 (June 2020): 859–60. http://dx.doi.org/10.1136/annrheumdis-2020-eular.3002.

Full text
Abstract:
Background:Several rheumatic conditions have been associated with increased risk of malignancies, especially hematopoietic and lymphoproliferative malignancies. Rheumatoid arthritis has been associated with a relative risk of 1.5-4 for the development of hematological malignancies (HM)1. A variety of immunosuppressive and immunomodulatory medications have also been linked to increased risk of HM2. Moreover, with advances in the field of biologic agents being used in the treatment of rheumatic diseases (RD), the landscape keeps changing. To our knowledge, data on general trends of HM as well as in RD is limited.Objectives:Our study aimed to determine the trends of hospitalizations for HM in patients with RD.Methods:We identified admissions with HM with underlying RD (including rheumatoid arthritis systemic lupus erythematosus, inflammatory myositis, scleroderma, polymyalgia rheumatica, and connective tissue disease) from the NIS database using International Classification of Diseases, Ninth Revision (ICD-9) diagnosis codes from years 2005 to 2014. The primary outcome was the trends in hospitalizations for HM. We studied the yearly trends and the types of HM among hospitalizations with or without RD.Results:906,556 weighted hospitalizations were estimated for HM, and amongst those, 17,675 had underlying RD. The demographic analysis suggested that the average age of hospitalizations with HM and RD was higher, were more often females, and a higher number of comorbidities (Table 1). The average number of admissions remained stable for HM with and without HM, as described in Graph 1. There was a significant difference in the frequency of various subtypes in patients with and without RD (Graph 2). Non-Hodgkin’s Lymphoma was the most common subtype in HM without and with RD (35.8% and 47.14%).Table 1.Baseline Demographics of Hospitalizations for HM with and without RDCharacteristicsHM without RDHM with RDp valueAge (in years ± SD)62.05 ± 0.2367.41 ± 0.29<0.05Gender (%)<0.05 Males55.9933.35 Female44.0166.65Race (%)<0.05 White71.2475.88 Black12.2711.31 Hispanic10.217.62 Asian or Pacific Islander2.662.01 Native American0.430.62 Other3.182.55Charlson Category (%)<0.05 255.073.76 321.8346.93 411.5523.71 55.5412.88 >=66.0112.73Type of Insurance (%)<0.05 Medicare49.4966.35 Medicaid10.936.04 Private35.826.19 Self-Pay3.781.42Conclusion:To our knowledge, this is the first study to analyze trends in HM with RD. There has not been any significant change in the number of hospitalizations for HM from 2005-2014 with or without RD. The most common HM in admissions with RD were Non-Hodgkin’s Lymphomas (NHL) and myeloid leukemias, followed by multiple myeloma. The trends suggest no significant change in subtypes of HM over the study period.Graph 1.Hospitalizations per year for Hematologic Malignancies With Rheumatic Diseases 2005-2014Graph 2.Types Of Hematological Malignancies In Hospitalizations With And Without Rheumatic Diseases (%)References:[1] Thomas E, Brewster DH, Black RJ, et al. Risk of malignancy among patients with rheumatic conditions. Int J Cancer 2000;88:497 –502.[2] Jones M, Symmons D, Finn J, et al. Does exposure to immunosuppressive therapy increase the 10 year malignancy and mortality risks in rheumatoid arthritis? A matched cohort study. Br J Rheumatol 1996;35:738 –45.Disclosure of Interests:None declared
APA, Harvard, Vancouver, ISO, and other styles
10

Abhishek, Abhishek, Annamaria Iagnocco, J. W. J. Bijlsma, Michael Doherty, and Frédéric Lioté. "Cross-sectional survey of the undergraduate rheumatology curriculum in European medical schools: a EULAR School of Rheumatology initiative." RMD Open 4, no. 2 (September 2018): e000743. http://dx.doi.org/10.1136/rmdopen-2018-000743.

Full text
Abstract:
ObjectivesTo survey the undergraduate rheumatic and musculoskeletal diseases (RMDs) curriculum content in a sample of medical schools across Europe.MethodsThe undergraduate musculoskeletal diseases and disability curriculum of University of Nottingham, UK, was used as a template to develop a questionnaire on curriculum content. The questionnaire elicited binary (yes/no) responses and included the option to provide additional information as free text. The survey was mailed to members of the European League Against Rheumatism (EULAR) School of Rheumatology (Undergraduate Classroom) and to EULAR Standing Committee on Education and Training members in January 2017, with a reminder in February 2017.ResultsResponses were received from 21 schools belonging to 11 countries. Assessment of gait, hyperalgesic tender site response and hypermobility were not included in many curricula. Similarly, interpretation of investigations undertaken on synovial fluid was taught in only 16 schools. While disease-modifying anti-rheumatic drugs and biological agents, and urate-lowering treatment were included in the curricula of 20 and 21 institutions, respectively, only curricula from 18 schools included core non-pharmacological interventions. Osteoarthritis, gout, rheumatoid arthritis, spondyloarthropathy, polymyalgia rheumatica and lupus were included in the curriculum of all institutions. However, common RMDs such as calcium pyrophosphate deposition, fibromyalgia, giant cell arteritis and bone and joint infection were included in 19 curricula.ConclusionThis survey highlights areas of similarities and differences in undergraduate curricula across Europe. It is hoped that the results of this survey will catalyse the development and agreement of a minimum core European Curriculum for undergraduate education in RMDs.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Rheumatic"

1

Lundström, Emeli. "Genetic studies of the HLA locus in rheumatic diseases." Stockholm, 2010. http://diss.kib.ki.se/2010/978-91-7409-852-5/.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Shinebaum, R. "Faecal flora and rheumatic diseases." Thesis, University of Leeds, 1985. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.355708.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Mohamed, Kotit Susy Natalia. "Rheumatic heart disease in Egypt." Thesis, Imperial College London, 2012. http://hdl.handle.net/10044/1/9752.

Full text
Abstract:
Rheumatic Heart Disease remains one of the most neglected cardiac conditions in children and young adults around the world. The pathogenesis is complex and remains elusive, and the clinical characteristics vary around the world. This thesis concentrates on different aspects of the disease in Egypt, where it is known to have a high incidence. The methodology included epidemiological studies in school children in Aswan and investigation of RHD in a population with history of RF, using newly developed echocardiographic criteria. Concomitantly, the pattern of immune response in RF and RHD was determined in serum and excised valves. In this series RF presents in children and young adults, as well as adults, (0.2-44 years, 10.69 ± 6.24) with polyarthritis being the most common clinical presentation (87.9%) and recurrences of RF being very common (98.2%). RHD affected 23 in 1000 school children in Aswan with over 90% of the cases being subclinical and developed in up to 69.2% of the individuals with history of RF, predominantly as mitral regurgitation. Risk factors for the development and severity of RHD were shown to be low disease awareness, non-compliance to penicillin prophylaxis or a regimen of longer than 15-days. Resistance to antibiotic regimens, including Penicillin and Vancomicin seems to lead to development and recurrences of RF in Egypt. This series showed the presence of immune activation and ongoing immunological reaction in an apparently quiescent phase of the disease with distortion of normal valvular architecture, histology and composition. This work has served to define the epidemiology, pattern of disease, immune reponse and predisposing factors in a population with no previous data, also contributing to the improvement of the echocardiographic diagnostic criteria. Standardization of the criteria will allow comparison of prevalence in different areas and improve case detection.
APA, Harvard, Vancouver, ISO, and other styles
4

Hatch, Lashley. "Statistical Information Included in Labeling for Disease-Modifying Anti-Rheumatic Drugs for Rheumatoid Arthritis." The University of Arizona, 2012. http://hdl.handle.net/10150/623641.

Full text
Abstract:
Class of 2012
Specific Aims: To evaluate the presence of statistical information from clinical studies in official product labeling specific for disease-modifying anti-rheumatic drugs (DMARDs) used in the treatment of rheumatoid arthritis. Methods: Data were abstracted from official product labeling DMARDs with FDA approval for treatment of rheumatoid arthritis. Each document was examined for the presence of statement regarding a priori type 1 error rate, p-values, and measures of variance. Medications were classified as either biologic or non-biologic. Main Results: A total of 14 DMARDs, 7 biologics (50%) and 7 non-biologics (50%), were found to be FDA approved for the treatment of rheumatoid arthritis. Primary outcomes consisted of American College of Rheumatology (ACR) response rates, radiographic changes, and health assessment questionnaire score (HAQ). Any measure of variance and the presence of a p-value were both found in six (43%) of the drug labels. Inclusion of p- values was found to be significantly greater in biologics compared to non-biologics for both ACR and radiographic results. Inclusion of variance was found to be significantly greater in biologics compared to non-biologics for radiographic changes only. No package inserts contained statements regarding the a priori type I error rate. Conclusions: Measures of variance are not frequently included in product labeling for either biologic or non-biologic DMARDs. However, inclusion of variance and p-values for ACR response rates and radiographic changes were more likely to be reported for biologics therapies as compared to non-biologics. A statement regarding Type 1 error rates were absent from labels regardless of outcome assessed.
APA, Harvard, Vancouver, ISO, and other styles
5

Hatch, Lashley, and Daniel C. Malone. "Statistical Information Included in Labeling for Disease-Modifying Anti-Rheumatic Drugs for Rheumatoid Arthritis." The University of Arizona, 2012. http://hdl.handle.net/10150/614497.

Full text
Abstract:
Class of 2012 Abstract
Specific Aims: To evaluate the presence of statistical information from clinical studies in official product labeling specific for disease-modifying anti-rheumatic drugs (DMARDs) used in the treatment of rheumatoid arthritis. Methods: Data were abstracted from official product labeling DMARDs with FDA approval for treatment of rheumatoid arthritis. Each document was examined for the presence of statement regarding a priori type 1 error rate, p-values, and measures of variance. Medications were classified as either biologic or non-biologic. Main Results: A total of 14 DMARDs, 7 biologics (50%) and 7 non-biologics (50%), were found to be FDA approved for the treatment of rheumatoid arthritis. Primary outcomes consisted of American College of Rheumatology (ACR) response rates, radiographic changes, and health assessment questionnaire score (HAQ). Any measure of variance and the presence of a p-value were both found in six (43%) of the drug labels. Inclusion of p-values was found to be significantly greater in biologics compared to non-biologics for both ACR and radiographic results. Inclusion of variance was found to be significantly greater in biologics compared to non-biologics for radiographic changes only. No package inserts contained statements regarding the a priori type I error rate. Conclusions: Measures of variance are not frequently included in product labeling for either biologic or non-biologic DMARDs. However, inclusion of variance and p-values for ACR response rates and radiographic changes were more likely to be reported for biologics therapies as compared to non-biologics. A statement regarding Type 1 error rates were absent from labels regardless of outcome assessed.
APA, Harvard, Vancouver, ISO, and other styles
6

Pandey, Sanjib Raj. "Temporal logic-based fuzzy decision support system for diagnosis of rheumatic fever and rheumatic heart disease." Thesis, University of Greenwich, 2016. http://gala.gre.ac.uk/18088/.

Full text
Abstract:
This is a collaboration project between the Nepal Heart Foundation (NHF) and the University of Greenwich (UoG), United Kingdom (UK). Our mutual aim, agreed at the outset, has been to analyse, design and develop a cost effective Clinical Decision Support System (CDSS) for diagnosis and recognition of Acute Rheumatic Fever (ARF) and Rheumatic Heart Disease (RHD) at an early stage by developing/adopting UK’s and NHF’s treatment practices and procedures that would be appropriate for the Nepalese environment and lifestyle. The Application we developed was designed for use by community health workers and doctors in the rural areas of Nepal where laboratory facilities, expert services and technology are often deficient. The research undertaken investigated three problems that previously had not been addressed in the Artificial Intelligence (AI) community. These are: 1) ARF in Nepal has created a lot of confusion in diagnosis and treatment, due to the lack of standard procedures; 2) the adoption of foreign guidelines is often not effective and does not suit the Nepali environment and lifestyle and 3) the value of combining (our proposed) Hybrid Approach (Knowledge-based System (KBS), Temporal Theory (TT) and Fuzzy Logic (FL)) to design and develop an application to diagnose ARF cases at an early stage in English and Nepali. This research presents, validates and evaluates a proposed Hybrid Approach to diagnose ARF at three different stages: 1) Detected; 2) Suspected and 3) Not-detected and also to identify the severity level of detected ARF in the forms of Severe Case, Moderate Case or Mild Case. The Hybrid Approach is a combination of the KBS/Boolean Rule Model, Temporal Model and Fuzzy Model. The KBS/Boolean Rule Model has four components for design and implementation of KBS. These are: identifying the ARF stage in a case; Rule Pattern Matching; New Rule Formation and Rule Selection Mechanism. The Temporal Model has four components namely: Descriptive Explanation of ARF symptoms; Temporal Lookup-Table/Rules and Temporal Reasoning which produce a Temporal Template for demonstrating the relationship between the signs and ARF. The Fuzzification, Fuzzy Inferences and Defuzzification components are applied to design and implement a Fuzzy Model. The research undertaken divided the overall ARF diagnosis problem, in effect its requirements, into several sub-problems and each model of the Hybrid Approach addressed particular sub-problems for example, Identify the stage of the ARF component of the KBS/Boolean Rule Model used to solve the question of identifying the stage of ARF based on the symptoms presented. Each problem was therefore handled using a particular model’s components. This significantly helped to improve maintainability, reliability and the overall quality of our final ARF Diagnosis Application. The developed ARF Diagnosis Application was experimentally tested and evaluated by NHF’s experts and users through applying NHF’s data sets consisting of 676 real patients’ records. The ARF Diagnosis Application was found to match 99% of the cases derived from NHF’s datasets. The overall ARF diagnostics performance and accuracy was 99.36%. Therefore, the experiments and evaluations of our ARF Diagnosis Application proved that it was logically and technically feasible to employ the Hybrid Approach for developing a new and practical ARF Diagnosis Application. The Application was ultimately developed and succeeded in embracing NHF’s requirements and guidelines thereby matching the Nepalese setting and making it suitable for use in Nepal having fully by met the exigencies of the Nepalese environment and lifestyle. Application of a new ARF diagnosis system (ours) proved that the Hybrid Approach, applied methods of diagnosis of ARF, medication and treatment plan, including help and supporting information which were identified and defined, were shown to be appropriate to support effectively community health workers and doctors who actively care for ARF and RHD cases in rural Nepal.
APA, Harvard, Vancouver, ISO, and other styles
7

Iwobi, Mabel Uzoamaka. "Salivary autoantigens in human rheumatic diseases." Thesis, University of Sussex, 1994. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.260048.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Cao, Duojia. "CD25+CD4+ regulatory T cells in rheumatic disease /." Stockholm, 2005. http://diss.kib.ki.se/2005/91-7140-178-4/.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Mohanty, Subhasis. "Role of pathogenic antibodies in rheumatic diseases." [S.l.] : [s.n.], 2003. http://deposit.ddb.de/cgi-bin/dokserv?idn=967642760.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Bakker, Carla Heleen. "Patient-oriented outcome assessment in rheumatic diseases." Maastricht : Maastricht : Universitaire Pers Maastricht ; University Library, Maastricht University [Host], 1995. http://arno.unimaas.nl/show.cgi?fid=7915.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Rheumatic"

1

A, Paget Stephen, and Fields Theodore R, eds. Rheumatic disorders. Boston: Andover Medical Publishers, 1992.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Paget, Stephen A. Rheumatic disorders. Boston: Andover Medical Publishers, 1992.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Network, Ohio Health Promotion, ed. Rheumatic. Columbus: Ohio Health Promotion Network, Ohio Dept. of Health, Bureau of Health Promotion and Education, 1992.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

1933-, Schumacher H. Ralph, Klippel John H, Robinson Dwight R, and Arthritis Foundation, eds. Primer on the rheumatic diseases. 9th ed. Atlanta, GA: Arthritis Foundation, 1988.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

H, Klippel John, ed. Primer on the rheumatic diseases. New York, NY: Springer, 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

1933-, Schumacher H. Ralph, Klippel John H, and Koopman William J, eds. Primer on the rheumatic diseases. Atlanta, Ga: Arthritis Foundation, 1993.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

H, Klippel John, ed. Primer on the rheumatic diseases. New York, NY: Springer, 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Klippel, John H., Cornelia M. Weyand, and Robert Wortmann. Primer on the rheumatic diseases. Edited by Klippel John H, Weyand Cornelia M, and Wortmann Robert. Atlanta, Ga: Arthritis Foundation, 1997.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Taranta, Angelo, and Milton Markowitz. Rheumatic Fever. Dordrecht: Springer Netherlands, 1988. http://dx.doi.org/10.1007/978-94-009-1261-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

1918-, Markowitz Milton, ed. Rheumatic fever. 2nd ed. Dordrecht: Kluwer Academic Publishers, 1989.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Rheumatic"

1

Fry, John. "Rheumatic." In The Beecham Manual for Family Practice, 211–24. Dordrecht: Springer Netherlands, 1985. http://dx.doi.org/10.1007/978-94-011-6361-3_17.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Taranta, Angelo, and Milton Markowitz. "Rheumatic recurrences." In Rheumatic Fever, 71–74. Dordrecht: Springer Netherlands, 1989. http://dx.doi.org/10.1007/978-94-009-1261-8_10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Hardy, Bruce G. "Rheumatic Heart Disease/Acute Rheumatic Fever." In Textbook of Clinical Pediatrics, 2425–32. Berlin, Heidelberg: Springer Berlin Heidelberg, 2012. http://dx.doi.org/10.1007/978-3-642-02202-9_258.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Reményi, Bo, Andrew Steer, and Michael Cheung. "Rheumatic Fever and Rheumatic Heart Disease." In Echocardiography in Pediatric and Congenital Heart Disease, 750–62. Oxford, UK: John Wiley & Sons, Ltd, 2016. http://dx.doi.org/10.1002/9781118742440.ch39.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Birmingham, Erin, and Randy Ray Richardson. "Rheumatic Fever and Rheumatic Heart Disease." In Atlas of Acquired Cardiovascular Disease Imaging in Children, 67–73. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-44115-3_11.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Awad, Sawsan Mokhtar M., and Daniel E. Felten. "Rheumatic Fever and Rheumatic Heart Disease." In Heart Diseases in Children, 317–23. Boston, MA: Springer US, 2011. http://dx.doi.org/10.1007/978-1-4419-7994-0_27.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Bahk, Yong-Whee. "Other Rheumatic Osteoarthropathies and Soft-Tissue Rheumatism SyndrOther Rheumatic Osteoarthropathies and Soft-Other Rheumatic Osteoarthropathies and Soft-Tissue Rheumatism Syndromes." In Combined Scintigraphic and Radiographic Diagnosis of Bone and Joint Diseases, 235–70. Berlin, Heidelberg: Springer Berlin Heidelberg, 2012. http://dx.doi.org/10.1007/978-3-642-25144-3_12.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Menon, Shaji C., and Lloyd Y. Tani. "Rheumatic Fever." In Pediatric Cardiovascular Medicine, 888–904. Oxford, UK: Wiley-Blackwell, 2012. http://dx.doi.org/10.1002/9781444398786.ch61.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Mandell, Brian F. "Rheumatic Disease." In Perioperative Medicine, 329–41. London: Springer London, 2011. http://dx.doi.org/10.1007/978-0-85729-498-2_28.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Sherer, Yaniv, and Yehuda Shoenfeld. "Rheumatic Fever." In Diagnostic Criteria in Autoimmune Diseases, 379–81. Totowa, NJ: Humana Press, 2008. http://dx.doi.org/10.1007/978-1-60327-285-8_69.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Rheumatic"

1

Pop, Petru A., Liviu Lazar, and Florin M. Marcu. "Specific Treatments for Improving the Quality of Life in Rheumatologic Affections and Osteoporosis." In ASME 2011 International Mechanical Engineering Congress and Exposition. ASMEDC, 2011. http://dx.doi.org/10.1115/imece2011-63929.

Full text
Abstract:
The analysis and implementation of modern treatments for the patients diagnosed with osteoporosis, degenerative rheumatic affections and peripheral circulatory disorders have become a healthy priority for the society. These treatments have the goal to raise the bone mineral density of the skeleton, reducing joints pain and inflammation while improving and maintaining joints function. This paper presents a conservative treatment of patients from Recovery Clinical Hospital of Felix Spa, diagnosed with degenerative and rheumatoid affections. The treatment is complex and involves balneal-physical-kinetic recovery therapy that must be periodical repeated at every six months to perform. Ankylosing spondylitis was been evaluated by BASFI-BASDAI scores, while the gonarthrosis with Artroflex by SF-36 of quality life scale and Lequesne index. In addition, a vibration treatment combined with balneal-conservative treatment was been proposed to reduce the therapy time and improved the quality live of patients. The vibration system comprises a vibration bed with adjusting control of signal by a digital frequency convertor, and a command panel system for measuring and processing of data. Because the vibration trial is in incipient experiment stage, it was been applied first on Wistar rats, due to increase the calcium mass of bones. The results of all treatments were emphasized the efficiency of balneal cure in rheumatic affections.
APA, Harvard, Vancouver, ISO, and other styles
2

Philippou, Elena. "SP0063 NUTRITION AND RHEUMATIC DISEASES." In Annual European Congress of Rheumatology, EULAR 2019, Madrid, 12–15 June 2019. BMJ Publishing Group Ltd and European League Against Rheumatism, 2019. http://dx.doi.org/10.1136/annrheumdis-2019-eular.8559.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Smith, V. "SP0112 Microcirculation in rheumatic diseases." In Annual European Congress of Rheumatology, EULAR 2018, Amsterdam, 13–16 June 2018. BMJ Publishing Group Ltd and European League Against Rheumatism, 2018. http://dx.doi.org/10.1136/annrheumdis-2018-eular.7792.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Ekbom, A. "SP0012 Malignancies in rheumatic diseases." In Annual European Congress of Rheumatology, Annals of the rheumatic diseases ARD July 2001. BMJ Publishing Group Ltd and European League Against Rheumatism, 2001. http://dx.doi.org/10.1136/annrheumdis-2001.54.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Wang, Julia Y. "GLYCOBIOLOGY AND AUTOIMMUNE RHEUMATIC DISEASES." In XXIst International Carbohydrate Symposium 2002. TheScientificWorld Ltd, 2002. http://dx.doi.org/10.1100/tsw.2002.682.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Mody, M., K. Edebiri, P. S. Patel, T. Anandarangam, and C. Migliore. "Rheumatic Obliteration of the Lung!!" In American Thoracic Society 2019 International Conference, May 17-22, 2019 - Dallas, TX. American Thoracic Society, 2019. http://dx.doi.org/10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a1526.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

LUCENA, GERMANA RIBEIRO ARAUJO CARNEIRO DE, PRISCILA DIAS CARDOSO RIBEIRO, DANIEL VIANA DA SILVA E. SILVA, RENAN RODRIGUES NEVES RIBEIRO DO NASCIMENTO, IGOR BELTRÃO DUARTE FERNANDES, MARIANA DAVIM FERREIRA GOMES, LUÍZA SÁ E. RÊGO TUPINAMBÁ, RAQUEL MITIE KANNO, ALEXANDRE LIMA MATOS, and EDGARD TORRES DOS REIS NETO. "SYPHILIS MIMICKING AUTOIMMUNE RHEUMATIC DISEASE." In 36º Congresso Brasileiro de Reumatologia. São Paulo: Editora Blucher, 2019. http://dx.doi.org/10.5151/sbr2019-263.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Cuervo, F. M., A. M. Santos, J. C. Rueda, I. Angarita, E. L. Saldarriaga, R. Giraldo, J. Ballesteros, et al. "AB1244 Quality life in patients with rheumatic disease, non-rheumatic diseases and healthy population." In Annual European Congress of Rheumatology, EULAR 2018, Amsterdam, 13–16 June 2018. BMJ Publishing Group Ltd and European League Against Rheumatism, 2018. http://dx.doi.org/10.1136/annrheumdis-2018-eular.4319.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Kuhn, Annegret. "SP0193 WIN: SKIN AND RHEUMATIC DISEASES." In Annual European Congress of Rheumatology, EULAR 2019, Madrid, 12–15 June 2019. BMJ Publishing Group Ltd and European League Against Rheumatism, 2019. http://dx.doi.org/10.1136/annrheumdis-2019-eular.8522.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

HELIALDO SOUSA DE OLIVEIRA FILHO, FRANCISCO, PRISCILA DOURADO EVANGELISTA, PRISCILA GARCIA CÂMARA CABRAL TAVARES, LUIZ VALÉRIO COSTA VASCONCELOS, MARINA PINTO ROCHA, ANA CAROLINA CAVALCANTE MENDONÇA, ADAH SOPHIA RODRIGUES VIEIRA, et al. "LEPROSY: INFECTIOUS DISEASE MIMICKING RHEUMATIC DISEASES." In SBR 2021 Congresso Brasileiro de Reumatologia. Sociedade Brasileiro de Reumatologia, 2021. http://dx.doi.org/10.47660/cbr.2021.1806.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Rheumatic"

1

Mamus, M. A., E. E. Mozgovaya, S. A. Bedina, S. S. Spitsina, and A. S. Trofimenko. International Journal of Rheumatic Diseases. DOI CODE, 2021. http://dx.doi.org/10.18411/aplar-2021-122.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Chen, Cheng-Che, and Chung-Jen Chen. New-Onset Inflammatory Arthritis After Covid-19 Vaccination. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, July 2022. http://dx.doi.org/10.37766/inplasy2022.7.0128.

Full text
Abstract:
Review question / Objective: Investigate the new-onset inflammatory arthritis after Covid-19 vaccination in patients without pre-existing autoimmune nor rheumatic diseases and analyze their clinical patterns. Condition being studied: To help the readers to understand the clinical patterns of new-onset inflammatory arthritis after Covid-19 vaccination in patients without pre-existing autoimmune nor rheumatic diseases. Eligibility criteria: Inclusion criteria: publications of new-onset inflammatory arthritis after Covid-19 vaccination in patients without pre-existing autoimmune nor rheumatic diseases between January 2020 to March 2022. Exclusion criteria: cases with arthritis after SARS-CoV-2 infection and arthritis reactivation in those with underlying or history of arthritis-associated or autoimmune diseases.
APA, Harvard, Vancouver, ISO, and other styles
3

Trofimenko, A., M. Mamus, S. Bedina, E. Mozgovaya, and S. Spitsina. PARTICIPATION OF NEUTROPHIL EXTRACELLULAR TRAPS IN AUTOIMMUNE RHEUMATIC DISEASES. DOI CODE, 2021. http://dx.doi.org/10.18411/wco-iof-esceo-2021-509.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Rusanova, O. A., O. I. Emelyanova, and A. S. Trofimenko. PATTERNS OF PLASMA ANTI-THYROID HORMONE ANTIBODIES IN AUTOIMMUNE RHEUMATIC DISEASES WITH THYROID LESION. DOI CODE, 2021. http://dx.doi.org/10.18411/wco-iof-esceo-2021-422.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Aleksandrov, A. V., L. N. Shilova, I. Yu Alekhina, N. V. Aleksandrova, N. V. Nikitina, and E. V. Benedickaya. COMBINED USE OF IMMUNOLOGICAL AND ULTRASOUND METHODS OF ESTIMATION OF VALVE HEART STATUS IN PATIENTS WITH INFLAMMATORY RHEUMATIC DISEASES. Планета, 2018. http://dx.doi.org/10.18411/978-5-907109-24-7-2018-xxxv-14-18.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Kalinina, E. V., A. R. Babaeva, A. V. Levickaya, and M. S. Zvonorencko. MULTIMORBIDITY IN RHEUMATOID ARTHRITIS. Планета, 2018. http://dx.doi.org/10.18411/978-5-907109-24-7-2018-xxxv-184-186.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Fox, David A. Citrullinated Chemokines in Rheumatoid Arthritis. Fort Belvoir, VA: Defense Technical Information Center, October 2014. http://dx.doi.org/10.21236/ada611994.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Kalinina, E. V., E. V. Krivospitskaya, A. R. Babaeva, and M. S. Zvonorenko. COMORBIDITY IN PATIENTS WITH RHEUMATOID ARTHRITIS. "PLANET", 2019. http://dx.doi.org/10.18411/978-5-907192-54-6-2019-xxxvi-112-119.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Deane, Keivn D. Pathogenesis and Prediction of Future Rheumatoid Arthritis. Fort Belvoir, VA: Defense Technical Information Center, October 2014. http://dx.doi.org/10.21236/ada613196.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Blanken, Annelies, Bafrin Abdulmajid, Eva van Geel, Joost Daams, Martin van der Esch, and Michael Nurmohamed. Effect of tumor necrosis factor inhibiting treatment on arterial stiffness and arterial wall thickness in rheumatoid arthritis patients: protocol for a systematic review and planned meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, January 2022. http://dx.doi.org/10.37766/inplasy2022.1.0131.

Full text
Abstract:
Review question / Objective: The aim of this systematic review is to evaluate the effect of TNF inhibiting treatment on arterial stiffness (as measured with pulse wave velocity and augmentation index) and arterial wall thickness (as measured with carotid intima media thickness) in rheumatoid arthritis patients. Condition being studied: Rheumatoid arthritis is a chronic autoimmune disorder, which affects approximately 1% of the population worldwide. Information sources: The following electronic databases will be searched for potentially eligible studies: EMBASE, MEDLINE, ClinicalTrials.gov and WHO International Clinical Trials Registry Platform. For the studies identified as eligible for inclusion, similarity tracking will be used to identify more potentially relevant articles with the ‘related article’ feature in PubMed. In addition, a citation search will be performed for included studies to identify articles that have cited them. Reference lists of the included studies and previous reviews on the subject will be searched for potentially relevant studies. ResearchGate profiles of top authors on the subject will be investigated to identify potentially relevant data points. For ongoing or finished studies that are potentially eligible, but without a publication, study authors will be contacted for information. When additional information is needed, study authors will be contacted as well.
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Rheumatic' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography